Equibles does not estimate personal net worth.
Tycho Peterson was last confirmed as CFO at Adaptive Biotechnologies Corp (ADPT) in a filing dated April 29, 2025. Earlier roles on record: CFO at Adaptive Biotechnologies Corp (ADPT) until April 5, 2024. Adaptive Biotechnologies Corp reported in an 8-K filed April 2, 2024 that Tycho Peterson resigned as Chief Financial Officer, effective April 5, 2024. The proxy statement of Adaptive Biotechnologies Corp reports total compensation of $1,667,102 for Tycho Peterson in fiscal 2024, including a base salary of $114,423. Disclosed compensation is on record for 3 fiscal years. Tycho Peterson has spoken on 7 earnings calls across 1 company, most recently for Adaptive Biotechnologies Corp on February 14, 2024. The companies whose calls Tycho Peterson spoke on are classified in the Healthcare sector.
“On April 1, 2024, the Chief Financial Officer of Adaptive Biotechnologies Corporation (the "Company") Tycho Peterson submitted his resignation.”
“Starting on Slide 15 with revenue for the fourth quarter and full year. Total revenue in the fourth quarter was $45.8 million with 67% from MRD and 33% from Immune Medicine.”
“Turning to our financials on Slide 7, total revenue in the third quarter was $37.9 million with 65% from MRD and 35% from Immune Medicine representing a 21% decline from the same period last year.”
“Total revenue in the second quarter was $48.9 million, with 53% from MRD and 47% from Immune Medicine, representing a 12% increase from a year ago, primarily attributable to growth from the clonoSEQ clinical business and the Genentech IND milestone.”
“I want to remind you that we had anticipated the year to be weighted towards the second half. When considering ClonoSEQ, keep in mind the EPIC integration we discussed earlier and the ramp-up in DLBCL.”
“Starting on Slide 11, with revenue for the fourth quarter and full year. Total revenue in the fourth quarter was $55.2 million, with 51% from MRD and 49% from immune medicine, representing a 46% increase from the same period last year.”
Start not stated–2025-04-29
Last confirmed by a filing; no departure on record
Start not stated–2024-04-05
Diagnostics & Research · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Adaptive Biotechnologies Corp (ADPT) | Former Chief Financial Officer | $114,423 | $1,667,102 |
| 2023 | Adaptive Biotechnologies Corp (ADPT) | Former Chief Financial Officer | $425,000 | $2,565,396 |
| 2022 | Adaptive Biotechnologies Corp (ADPT) | Former Chief Financial Officer | $247,917 | $5,938,257 |
